Pharmacia & Upjohn consumer sales fall 2.1% in 1995 due to lower Motrin IB volume.
This article was originally published in The Tan Sheet
Executive Summary
PHARMACIA & UPJOHN CONSUMER PHARMACEUTICALS 1995 SALES FALL 2.1% to $441.5 mil. worldwide, because of lower Motrin IB sales, the firm said in a Feb. 22 release. The decline in sales for the analgesic was attributed to retail inventory reductions early in the year. The 1995 decline for Motrin IB follows a 12% gain in sales for the brand in 1994.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning